About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1/2NCT00147875

Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma

The objectives of this study are to assess the feasibility and efficacy of a combination chemotherapy (PVAG) in elderly patients with advanced stages Hodgkin's lymphoma.

Lead sponsor: University of Cologne•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Cologne

Collaborators

German Hodgkin's Lymphoma Study Group
Eli Lilly and Company

Gemcitabine shows promising activity in patients with relapsed lymphoma either administered as single agent or in combination with other cytotoxic agents. No trial to date evaluated its role in patients with primary Hodgkin's lymphoma. We therefore developed a three-weekly regimen based on the standard ABVD regimen.

Age

60 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Hodgkin's lymphoma (histologically proven)
•Clinical stage IIB (with risk factors bulky mediastinal mass and/or extranodal involvement), III, or IV
•No prior antitumor therapy
•Age 60 to 75 years
•WHO performance status 0-2
•Normal pulmonary function
•Written informed consent

Exclusion Criteria

•The following histologies are excluded: lymphocyte predominant HD
•Leukocytes \< 2,500/microL
•Platelets \< 100,000/microL

Related studies

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

NCT00131014 · Non-Hodgkin's Lymphoma, Hodgkin's Disease, and more

RECRUITINGPhase 2

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

NCT05346809 · Lymphoma, Multiple Myeloma, and more

RECRUITINGPhase 4

Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.

NCT03500133 · Pediatric Hodgkin's Disease

RECRUITINGPhase 2/3

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

NCT05595447 · Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, and more

Active Not RecruitingPhase 1

Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)

NCT00368082 · Lymphoma, Hodgkin's Disease, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 7, 2009Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment60

Start dateMar 2004

Last updatedSep 7, 2009

Condition

Hodgkin's Disease

Locations shown

University of Cologne

Cologne, North Rhine-Westphalia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 7, 2009Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions